Life Science Compliance Update

June

2018

Maryland Loses Rx Price Gouging Law But Not The Debate

Written by , Posted in Uncategorized

Nicodemo (Nico) Fiorentino, Esq.

Recently the United States Court of Appeals for the Fourth Circuit overturned Maryland’s law prohibiting price gouging for essential off–patent or generic drugs. This article highlights Maryland’s first-in-the-nation prescription drug price gouging legislation, key points to the commerce clause, and the impact the court’s ruling has on similarly proposed legislation throughout the country.


   or   

Topic tags:

April

2018

The Day After Tomorrow – The Drug Pricing Transparency Chorus Grows Louder

Written by , Posted in Uncategorized

Nicodemo Fiorentino, Esq. and Seth B. Whitelaw, J.D., LL.M., S.J.D.

Drug pricing transparency, as a concept at least, is here to stay. However, the details of what that means and the new obligations that pharmaceutical companies will need to deal with are yet to be determined. For pharmaceutical compliance professionals, 2018 will continue to be a time of high uncertainty and an ever-increasing workload. This article examines the current state and what the future may hold.


   or   

Topic tags:

Gravityscan Badge
Menu Title